BeiGene, Ltd. Sponsored ADR is a company in the U.S. stock market and it is a holding in 44 U.S.-traded ETFs. BGNE has around 1.3M shares in the U.S. ETF market. The largest ETF holder of BGNE is the iShares NASDAQ Biotechnology ETF (IBB), with approximately 428.07K shares. Investors may also find of interest that the ETF with the largest allocation to BGNE stock is Loncar Cancer Immunotherapy ETF (CNCR), with a portfolio weight of 4.40%. On average, U.S. ETFs allocate 0.59% of BGNE to their portfolios.
Additionally, BGNE is a favorite stock for Vanilla and Multi-factor ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with BGNE as a holding is the First Trust Chindia ETF (FNI), with a return of 55.44%.